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Multiple myeloma (MM) is a common malignant hematological disease. Dysregulation of microRNAs (miRNAs) in MM cells 
and bone marrow microenviroment has important impacts on the initiation and progression of MM and drug resistance in MM 
cells. Recently, it was reported that MM patient serum and plasma contained sufficiently stable miRNA signatures, and circu-
lating miRNAs could be identified and measured accurately from body fluid. Compared to conventional diagnostic parameters, 
the circulating miRNA profile is appropriate for the diagnosis of MM and estimates patient progression and therapeutic out-
come with higher specificity and sensitivity. In this review, we mainly focus on the potential of circulating miRNAs as diag-
nostic, prognostic, and predictive biomarkers for MM and summarize the general strategies and methodologies for identifica-
tion and measurement of circulating miRNAs in various cancers. Furthermore, we discuss the correlation between circulating 
miRNAs and the cytogenetic abnormalities and biochemical parameters assessed in multiple myeloma. 
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Multiple myeloma (MM) accounts for approximately 13% 
of all hematologic malignancies and 1% of all malign- 
ancies [1,2]. MM is a clonal B-cell malignancy character-
ized by the expansion of clonal plasma cells in the bone 
marrow, accompanied by abnormal accumulation of mono-
clonal antibodies [3,4]. Typically, MM evolves from a 
premalignant condition known as monoclonal gammopathy 
of undetermined significance (MGUS). The incidence of 
MGUS is approximately 3% in the general population 50 
years of age or older, and approximately 1% of MGUS pa-
tients develop into MM each year [1]. Compared to MM, 
MGUS is characterized by a lower concentration of serum 
monoclonal antibody, less bone marrow plasmacytosis and 
a lack of organ damage, including hypercalcemia, renal im-
pairment, anemia and bone lesions. Currently, there are no 
specific tests for distinguishing between these two condi-
tions and estimating the risk of progression from MGUS to 
MM. Additionally, no current strategies exist to prevent the 
progression from MGUS to MM; therefore, novel bio- 
marker which may predict progression is urgently needed in 
MGUS patients. 
miRNAs are an abundant class of regulatory noncoding 
single-stranded RNA molecules approximately 20–23 nu-
cleotides long. In general, miRNAs bind with imperfect 
complementarity to the 3′-untranslated region (3′-UTR 
(untranslated regions)) of a specific target mRNA to pro-
mote its degradation and/or inhibit its translation [5]. Many 
miRNAs display regulatory roles in all major biological 
processes, including cell motility, differentiation, prolifera-
tion and apoptosis [6,7]. Aberrant miRNA expression pro-
files are frequently discovered during the initiation and pro-
gression of cancers, including early or advanced disease 
stages, response, remission and relapse. Recently, it has 
been demonstrated that miRNAs are secreted into body flu-
ids, including serum and plasma, and can maintain stability 
while freely circulating in the bloodstream. 
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1  miRNAs and MM 
As growing research has indicated that miRNAs played 
important roles in the occurrence, development, recurrence 
and drug resistance of MM, miRNA signatures may serve as 
potential biomarkers for myeloma diagnosis, prognosis, and 
response to treatment. For example, hemizygous and/or 
homozygous chromosomal deletion at the 13q14 locus in 
MM patients can result in the loss of or reduction in expres-
sion of miR-15 and miR-16, which is correlated with tu-
morigenesis and the development of MM [8,9]. Pichiorri et  
al. [10] first described comprehensive global miRNA ex-
pression profiling of MM, MGUS and normal plasma cells, 
which indicated that MM miRNA signatures modulated the 
expression of proteins critical to myeloma pathogenesis. In 
2010, Gutierrez et al. [11] investigated the association be-
tween miRNA expression profiles and their corresponding 
target genes and found that the downregulation of several 
miRNAs resulted in overexpression of cyclin D2 (CCND2) 
in MM. These authors demonstrated for the first time that 
miRNA expression patterns in MM were associated with 
genetic abnormalities. Yyusnita et al. [12] revealed that 
several miRNAs, including downregulated let-7c and 
miR-16 and upregulated miR-449, miR-181a and 
miR-181b, exhibited similar expression patterns in periph-
eral blood compared to data obtained from bone marrow 
aspirates of MM patients. However, certain miRNAs, in-
cluding miR-21, the miR-106b-25 cluster and miR-181a/b, 
promoted oncogenic activity during the malignant transfor-
mation of plasma cells in MM and MGUS [10]. Further-
more, patients with high expression levels of the miR-17-92 
cluster had shorter progression-free survival (PFS) com-
pared to those with low level expression, suggesting that 
this cluster of miRNAs was associated with tumorigenesis 
and poor prognosis in MM [13]. Additionally, miR-21 may  
display an oncogenic role in MM; therefore, antagonism of 
miR-21 by oligonucleotide inhibitors may result in anti-
tumor activity against MM [14]. More recently, circulating 
miRNAs in body fluids (serum and plasma) have been 
shown to be significantly associated with MM pathogenesis.  
Recently, a variety of evidences suggested interaction 
between MM cells and bone marrow microenvironment 
(BMME) components played an increasingly important role 
in MM pathogenesis and progression. Aberrant expression 
of some miRNAs in MM-BMSCs (bone marrow stromal 
cells) or exosome resulted in altered expression of 
miR-related targets including cytokines, adhesion mole-
cules, DNA methyltransferase and signaling molecules (Ta-
ble 1) [15–21]. It has been confirmed that interleukin-17 
(IL-17) produced by the tumor microenvironment played a 
crucial role in promoting cell proliferation, inhibiting cellu-
lar and facilitating cell migration. Sun et al. demonstrated 
that negative correlation between miR-192 expression and 
IL-17 or IL-17RA expression was observed in bone marrow 
specimens derived from MM patients [15]. Furthermore, 
Shen et al. [16] indicated that miR-202 served as a negative 
modulator that can regulate BAFF by inhibiting MM cell 
survival, growth, and adhesion in BMME. Up-expression of 
miR-202 in BMSCs resulted in MM cells more sensitive to 
bortezomib. More interestingly, a recent study suggested 
that exosomal miR-135b endosome-derived from hypox-
ia-resistant MM (HR-MM) cells can control MM angiogen-
esis through directly inhibiting the expression of fac-
tor-inhibiting hypoxia-inducible factor 1 (FIH-1) in endo-
thelial cells [17]. 
2  Biogenesis and strategies for the identifica-
tion of circulating miRNA in cancer 
It remains unclear whether cell-free tumor-related miRNAs  
Table 1  Overview of specific miRNAs and their role in the MM microenviroment 
miRNA 
Up-regulation/ 
Down-regulation Gene targets Description of miRNAs functions Reference 
miR-192 miR-215  Down-regulation IL-17Rs(IL-17RA and IL-17RE) 
IL-17/miR-192/IL-17Rs regulatory feedback loop 
regulated MM cell proliferation, apoptosis and migra-
tion 
[15] 
miR-202 Down-regulation B cell-activating factor (BAFF) 
Regulating MM cell survival, growth, and adhesion in 





factor 1 (FIH-1) 
Exosomal miR-135b suppressed FIH-1 in endothelial 
cells and regulated tumor angiogenesis [17] 
miR-126-3p 
miR-140 
Down-regulation DNA methyltransferase-1  
(DNMT-1) 
miR-126-3p and miR-140 suppressed DNMT1 expres-
sion and re-expressed RANKL in MM cells 
[18] 
miR-29b Down-regulation DNMT-3A and DNMT-3B 
miR-29b inhibited DNMT-3A and DNMT-3B expres-
sion and reduced global DNA methylation  
[19] 
miR-21 Up-regulation RhoB 
Induction of BMSC-mediated drug resistance in MM 
cells partially through NFB pathway and by repress-
ing RhoB  
[20] 
miR-15a/16 Down-regulation Not mentioned 
IL-6 secreted by BMSCs inhibited miR-15a/16 ex-
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in the circulation are secreted by tumor cells or immuno-
cytes in the tumor microenvironment or are the by-product 
of tumor cell death and lysis. One hypothesis is that passive 
release occurs during cell injury [22]. A second opinion is 
that the high rate of proliferation and cell lysis in tumors 
might contribute to the abundance of miRNAs in the circula-
tion because a pattern of nonspecific miRNA release has been 
observed in various tumors [23]. Furthermore, the third pos-
sibility is that massive circulating miRNAs derive from im-
munocytes in the tumor microenvironment or the immune 
response regulated by the appropriate organ system [24]. 
Cell-free miRNAs in the blood stream are very stable and 
can be protected from degradation by encapsulation in lipid 
vesicles including microvesicles, exosomes, and apoptotic 
bodies. These vesicles are capable of binding with argo-
naute 2 (AGO2), nucleophosmin 1 (NPM1) and high- den-
sity lipoprotein (HDL). Additionally, understanding the 
origins of circulating miRNAs requires insight into the as-
sociation between expression levels of circulating miRNAs 
and the corresponding tumor cells that they affect. Most 
studies found consistent trends between changes in tumor 
tissue miRNAs and those observed in circulating    
miRNAs [25,26]. However, some of the cellular miRNAs 
may be selectively released into the serum [27]. Therefore, 
it is feasible to distinguish pathogenesis from normal physi-
ology by the detection of certain circulating miRNAs origi-
nating from different tissue cells.  
In general, strategies for identifying tumor-related circu-
lating miRNAs employ similar methodologies among vari-
ous cancers (Figure 1). The first step is efficient extraction 
and purification of miRNAs from serum or plasma. It is 
important to avoid miRNA degradation and contamination  
 
 
Figure 1  Flow chart of experimental design for the identification of 
circulating miRNA biomarkers in cancer.  
by additional substances in body fluids. Contaminations 
may result from the presence of intact blood cells in the 
serum or plasma or lysis of these cells (hemolysis) during 
sampling and processing [28–30].  
After purification, it is vital to obtain global profiles of 
miRNA signatures and compare the differential expression  
of miRNAs between tumor patients and healthy controls 
using the following three methodologies: qRT-PCR, miR-
NA microarray, and next-generation sequencing (NGS). 
Diagnostics based on circulating miRNAs rely on accurate 
measurements of miRNAs from the serum or plasma with 
high sensitivity and precision. Real time RT-PCR has been 
widely used as a sensitive and precise tool to detect 
low-abundance circulating miRNAs; however, there are 
crucial methodological challenges involved in the normaliza-
tion during detection of circulating miRNAs. Recent studies 
have indicated that a combination of several miRNAs can 
serve as a stable reference for the normalization of circulating 
miRNAs, and this method is statistically superior to the single 
reference gene approach previously used [31,32]. Moreover, 
to accurately determine the differential expression of miR-
NAs between groups, absolute quantification of circulating 
miRNAs appears to be the more reliable way. NGS and 
microarray are also effective techniques for identification of 
circulating miRNAs, but are less frequently used due to 
increased starting material requirements. Furthermore, the 
validation of NGS and microarray data need subsequently 
perform at the individual patient level by qRT-PCR. In par-
ticular, the application of NGS and microarray techniques is 
challenging for most laboratories as these approaches are 
expensive to validate and NGS itself remains costly and 
labor intensive. These issues may explain why qRT- 
PCR-based profiling strategies are more frequently     
used [33]. However, NGS has the notable advantage of dis-
tinguishing among unknown RNA species that would not be 
amplified by qRT-PCR. This may correlate with the emerg-
ing notion that miRNA 5′- and 3′-end structural variants, 
termed isomiRs, are frequently expressed and have been 
linked to tumorigenesis [34].  
3  Diagnostic, prognostic and predictive bi-
omarkers of circulating miRNA in MM 
Distinctive circulating miRNAs profiles may be observed in 
MM patients compared to healthy donors and MGUS pa-
tients, and this provides an important auxiliary tool for dis-
tinguishing MM patients from healthy controls and MGUS 
patients (Table 2). Kubiczkova et al. [35] obtained serum 
miRNA expression profiles by taqman low density arrays 
(TLDA), and validated these results by qRT-PCR in a co-
hort of newly diagnosed, relapsed MM and MGUS patients. 
A combination of miR-34a and let-7e could distinguish MM 
patients from healthy individuals with a sensitivity of 80.6% 
and a specificity of 86.7%; MGUS patients could be distin-
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Table 2  Synopsis of the potential of circulating miRNAs as biomarkers of MM 




Newly diagnosed MM patients (n=103) 
vs MM patients in relapse (n=18) vs 
MGUS (n=57) vs healthy donors (n=30) 
Taqman low density miRNA ar-








MGUS patients (n=15) vs MM patients 
(n=24) vs normal hospitalized controls 
(n=20) vs normal healthy controls (n=13) 




Symptomatic MM (n=138) vs smolder-
ing MM (n=8) vs MGUS (n=22) vs 
healthy volunteers (n=21) 
Taqman low density miRNA ar-



















Serum MM patients (n=40) vs healthy controls 
(n=30) 
qRT-PCR miR-202  [39] 
Plasma 
Newly diagnosed MM patients (n=40) vs 
healthy individuals (n=20) Microarray and qRT-PCR miR-483-5p miR-20a [40] 
Serum 
Newly diagnosed symptomatic MM 
patients (n=108) vs healthy donors 
(n=56) 









MM patients (n=40) vs healthy controls 
(n=28) 
Taqman low density miRNA ar-








MM patients (n=38) vs MGUS (n=8) vs 
healthy controls vs paired MM patients 
(n=17) at CR and relapse after autolo-
gous stem-cell transplantation (ASCT) 
TaqMan human microRNA 








guished from healthy donors with a sensitivity of 91.1% and 
a specificity of 96.7%. Jones et al. [36] revealed that circu-
lating miR-720 and miR-1246 were upregulated, and 
miR-1308 downregulated in MM patient sera. Further study 
found that the combination of miR-720 and miR-1308 was 
useful in distinguishing healthy controls, as well as patients 
with unrelated diseases from pre-cancerous myeloma and 
MM patients. Additionally, miR-1246 and miR-1308 ex-
pression could distinguish MGUS from MM patients [36]. 
Furthermore, low expression of plasma miR-92a in symp-
tomatic MM patients was found compared with healthy do-
nors [37]. As previously reported, miR-92a was identified 
as the most important potential diagnostic marker in several 
malignancies, including colorectal cancer [44], breast  
cancer [27], non-Hodgkin’s lymphoma [45], and gastric 
cancer [46]. The upregulation of miR-29a was helpful in 
discrimination between MM and healthy donors with a sen-
sitivity of 88% and a specificity of 70% [38]. The miR-202 
expression was significantly higher in MM patients than in 
healthy controls, and the sensitivity and specificity for 
miR-202 in this diagnosis of MM patients were 80.0% and 
60.0%, respectively [39]. Recently, increased miR-483-5p 
and decreased miR-20a expression display a diagnostic  
role in discriminating between MM patients and healthy 
subjects [40]. Furthermore, Hao et al. [41] found that a 
combination of miR-19a and miR-4254 could distinguish 
MM patients from healthy controls with a sensitivity of 
91.7% and a specificity of 90.5%. 
More recently, some studies have supported the fact that 
circulating miRNAs could function as non-invasive bi-
omarkers to estimate the prognosis of MM patients. 
miR-744 and let-7e were verified as possible indicators of 
survival in MM, and low miR-744 and let-7e levels were 
associated with shorter overall survival (OS) and remission, 
and shorter time to progression compared to patients with 
high expression of these molecules [35]. These poor clinical 
outcomes can be partially explained by the fact that the gene 
for miR-744 is located in the 17q12 region where various 
tumor-related genes are closely situated, including TP53, 
BRCA1, and FBXO47. Deletion of chromosome 17q12 has 
been previously associated with poor survival in can-   
cers [47,48]. Furthermore, the high levels of circulating 
miR-20a was positively correlated with miR-148a and 
shorter relapse-free time (RFT) in MM patients [42]. Addi-
tionally, expression of some miRNAs showed dynamic 
changes in MM plasma or serum during disease progres-
sion, and thus, continual detection of miRNA levels was 
beneficial for monitoring disease status and assessing the 
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prognoses of MM patients. Yoshizawa et al. [37] found that 
differential expression of miR-92a in different stages of 
MM. miR-92a plasma levels were lower in partial MM pa-
tients and did not normalize normal in subjects with a par-
tial response (PR) or very good PR to treatment, however, 
miR-92a levels did reach baseline in subjects who achieved 
complete remission. A recent study indicated that high 
miR-92a serum levels showed an independent correlation 
with poor survival in colorectal cancer [49]. The detection 
of miR-34a and let-7d was helpful in assessing the progno-
sis of MM, and high miR-34a expression and low let-7d 
expression were observed in relapsed MM patients com-
pared to levels in patients at the time of diagnosis [38]. Qu 
et al. [40] revealed that miR-483-5p showed association 
with PFS, and the median PFS was 15 mon in patients with 
high miR-483-5p levels compared to 21 mon in patients 
with low miR-483-5p levels.  
MGUS is usually referred as an asymptomatic precan-
cerous stage of malignant expansion of a clonal plasma cell. 
A good biomarker is urgently required and would be of 
great value for predicting MM tumorigenesis in MGUS pa-
tients and discriminating between these two conditions. Re-
cently, Jones et al. [36] revealed that the combination of 
miRNA-1246 and -1308 expression can distinguish MM 
from MGUS with a sensitivity of 79.2% and a specificity of 
66.7%. Unfortunately, no single serum miRNA was able to 
discriminate between these two conditions. Moreover, 
plasma miR-92a concentration may serve as a biomarker for 
monitoring the therapeutic response and assessing disease 
progression from MGUS to MM. The miR-92a plasma level 
in MUGS patients was significantly higher compared to that 
in MM patients, but there was no significant difference in 
plasma miR-92a levels between MM patients with smol-
dering disease and MGUS patients. Furthermore, the ex-
pression of plasma miR-92a in MGUS patients maybe act as 
a promising parameter not only for determining disease sta-
tus but also whether further treatment was required [37]. 
Reportedly, combination with miR-19b and miR-331 was a 
marker of shorter PFS, because longer PFS after ASCT was 
associated with high expression of miR-19b or miR-331 in 
MM patients [43]. 
4  Circulating miRNA expression patterns are 
associated with biochemical parameters in MM 
Spearman bivariate correlation was performed to understand 
the relevance of circulating miRNA expression levels to 
clinical parameters in MM patients (Table 3). The results 
indicated that expression levels of four miRNAs (miR-744, 
miR-130a, let-7d and let-7e) showed positive correlations 
with hemoglobin and thrombocyte counts; however, expres-
sion of these miRNAs was also negatively correlated with 
levels of creatinine and 2-microglobulin. Furthermore, 
miRNA-34a was negatively correlated with hemoglobin. 
Three circulating miRNAs including miR-744, let-7d and 
let-7e were positively correlated with albumin levels, 
whereas miRNA-34a showed a significant negative correla-
tion with albumin. In particular, let-7e levels showed sig-
nificant negative correlations with the level of monoclonal 
immunoglobulin [35]. Jones et al. [36] demonstrated that 
miR-1246 showed a slight significant inverse correlation 
with paraprotein (M-protein), which indicated that miR-
NA-1246 expression may be suppressed by increased 
paraprotein production or secretion. Yu et al. [39] found 
that the relative expression of serum miR-202 was higher in 
MM patients compared to healthy subjects, and significantly 
positively correlated with serum 2-microglobulin and  
light chain concentrations but was not correlated with the 
lactic acid dehydrogenase (LDH) and  light chain concen-
trations. 
5  Circulating miRNA expression is associated 
with cytogenetic abnormalities in MM 
Detailed genomic analysis has revealed that MM was char-
acterized by complex cytogenetic abnormalities, such as 
chromosomal translocations involving mutations of t(4;14), 
t(6;14) and t(14;16); deletion of 13q14 and 17p13; rear-
rangement of immunoglobulin heavy-chain genes (IGH); 
and amplification of 1q21 [50–53]. The tumor suppressor 
p53 which is located in 17p13.1 is rarely inactivated by  
Table 3  Correlation between circulating miRNAs and biochemical parameters in MM 
miRNA Biochemical parameters Negative/Positive References
miR-130a, miR-744, let-7d, let-7e   Hemoglobin Positive [35] 
Thrombocytes count Positive 
Creatinine and 2-microglobulin Negative 
let-7d, let-7e,  miR-744 Albumin Positive 
let-7e,  miR-744 C-reactive protein (CRP) Negative 
let-7e Monoclonal immunoglobulin (Ig) Negative 
miR-34a Hemoglobin Negative 
Albumin Negative 
miR-1246 Paraprotein (M-protein) Negative [36] 
miR-202 2-microglobulin and  light chain concentrations Positive [39] 
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Table 4  Correlation between circulating miRNAs and cytogenetic abnormalities in MM 
miRNA Cytogenetic abnormalities Negative/Positive References 
let-7e, miR-744 del(13q) Negative [35] 
miR-19a del(13q14) and 1q21 amplification Positive [41] 
miR-99b t(4;14) Positive [42] 
miR-211 del(13q) Negative [42] 
 
mutations or deletions, the ectopic expression of p53 can 
downregulate miR-192, miR-194, and miR-215 in a subset 
of newly diagnosed MM patients. These miRNAs serve as 
enhancers in the pharmacological activation of the p53 
pathway, in addition, they target the insulin-like growth 
factor (IGF) pathway, preventing enhanced migration of 
plasma cells into bone marrow [54]. Huang et al. [42] in-
vestigated the cytogenetic aberrations of 12 MM patients 
using micro-FISH, and detected serum miRNA expression 
by qRT-PCR. Interestingly, a high level of miR-99b expres-
sion was associated with a t(4;14) translocation (IGH; 
FGFR3) (Table 4), which suggested that miRNA-99b may-
be promote oncogenesis in MM. Furthermore, the presence 
of a t(4;14) chromosomal abnormality consistently indicated 
poor prognosis in MM patients [55]. Deletion of chromo-
some 13 was a common cytogenetic abnormality in MM 
and was associated with the clonal expansion of MM   
cells [8,9,56]. miR-221, an important oncogenic miRNA, 
was upregulated in numerous MM patients [57,58]. Expres-
sion of plasma miR-221 was specifically upregulated in the 
sera of MM patients compared to healthy controls, however, 
the miR-221 expression level was lower in MM samples 
with del(13q) than in those without del(q13) [42]. In addi-
tion, the presence of del(13q14) in MM patients has a sig-
nificant correlation with lower levels of let-7e, as well as 
miR-744, in the serum, which indicated worse OS and time 
to progression (TTP) [35]. Several studies have reported 
that lower levels of miR-744 were associated with 1q12 
amplification or t(4;14) in MM cells, both of which have 
been previously described as poor prognostic indicators for 
MM [59,60]. 
6  Circulating miRNA expression is associated 
with drug resistance in MM 
miRNA expression profiles are useful for prognosticating 
clinical resistance in MM patients. Aberrant expression of 
numerous miRNAs has also been observed in the 
drug-resistant myeloma cell lines, suggesting that dysregu-
lated miRNA might be involved in the generation of drug 
resistant MM cells [61,62]. Hao et al. [21] identified that 
miRNA-15a/-16 expressions significantly correlated with 
drug resistance of MM cells. Expression of miRNA-15a/-16 
was suppressed by interleukin-6 (IL-6) produced by 
BMSCs, which resulted in significantly increasing growth 
and survival of MM cells after treatment with cytotoxic 
agents. Serum miR-19a can function as a valuable predictor 
of PFS and OS in MM patients. MM patients with low 
miR-19a levels had improved responses to bortezomib 
compared to subjects with high miR-19a expression, expe-
rienced a significantly extended survival upon borte-
zomib-based therapy [41]. Qu et al. [40] indicated that the 
median PFS of patients with high levels of plasma 
miR-483-5p was 15 mon, in comparison with 21 mon for 
patients with low levels of plasma miR-483-5p after appli-
cation of several chemotherapy regimens including TAD, 
VD, TCD, PAD, TD and VTD. 
7  Conclusions 
Exploration of circulating miRNAs as novel biomarkers for 
MM is still a “booming” field. Growing studies indicate that 
the expression profiles of circulating miRNAs are valuable 
tools to diagnose patients and estimate prognosis as well as 
predicting response to treatment, clinical therapeutic out-
comes, and disease recurrence. However, some critical 
problems must be resolved to establish circulating miRNAs 
as biomarkers for MM. First, it is helpful to understand 
whether circulating miRNAs originate from tumor cell 
death and lysis, or instead from secretion by tumor cells or 
immunocytes in blood circulation. Furthermore, identifying 
the relationship between tissue miRNAs and circulating 
miRNAs will be valuable to elucidate the origin and func-
tion of circulating miRNAs. Second, to improve the diag-
nostic accuracy of this approach, a well-characterized panel 
of miRNAs specific to MM, MGUS, and chemotherapeutic 
responses should be established. Finally, larger sample sets 
including long-term clinical data are urgently required for 
future studies because these recent results are from small 
studies that lack long-term outcome data. In the coming 
years, we believe that widespread application of miRNA 
biomarkers in clinical practice will become routine in the 
diagnosis, prognosis and prediction of MM. 
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